MYH9 and acute lymphoblastic leukemia: The study suggests that this effect might be correlated with an impaired migration ability and an inefficient transendothelial migration process in MYH9 KD ALL cells, pointing out MYH9 as a potential therapeutic target to prevent ALL dissemination [191].